Search
OpenAI Plans to Use AI to Help Pharmaceutical Companies in R&D and Profit from It
6 hour ago /
Read about 0 minute
Author：小编
On February 4, OpenAI founder Altman stated that the company may consider investing in or subsidizing companies that extensively utilize its artificial intelligence technology to develop new drugs or therapies, and may seek returns by charging patent or usage fees. Altman said on Tuesday that AI developers could collaborate with pharmaceutical companies to jointly bear the costs of using AI models and receive a percentage of the returns from research results. He pointed out that such collaborations have not yet been initiated. Altman also mentioned that at the forefront of scientific exploration in artificial intelligence, the amount of funding required is substantial, so in some cases, OpenAI may become an investor in relevant projects.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
